Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Protalix BioTherapeutics, Inc. (DE) Common Stock (NY:PLX)

2.660 +0.230 (+9.47%)
Streaming Delayed Price Updated: 12:55 PM EDT, Aug 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Protalix BioTherapeutics, Inc. (DE) Common Stock

< Previous 1 2 3 4 Next >
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
Via Chartmill
Discover the top movers in Wednesday's pre-market session. ↗
Via Chartmill
PLX Shares Jump 13% On EMA Committee’s Turnaround On New Dosing Regimen For Fabry Disease Therapy ↗
Via Stocktwits
News headline image
Earnings Scheduled For November 13, 2025 ↗
 
Via Benzinga
News headline image
Preview: Protalix BioTherapeutics's Earnings ↗
 
Via Benzinga
News headline image
Top stock movements in today's session. ↗
Looking for insights into the US markets in the middle of the day on Friday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. 
Via Chartmill
Protalix BioTherapeutics Stock Tumbled 28% Today: Why The Latest CHMP Opinion Is Sparking Concerns Among Investors? ↗
Via Stocktwits
News headline image
Earnings Scheduled For August 14, 2025 ↗
 
Via Benzinga
News headline image
Why Is Protalix BioTherapeutics Stock Falling On Friday? ↗
EMA issues a negative opinion on Protalix and Chiesi's Elfabrio revised dosing for Fabry disease, citing insufficient data to confirm efficacy. 
Via Benzinga
News headline image
Which stocks are gapping on Friday? ↗
Traders are paying attention to the gapping stocks in Friday's session. Let's dive into which stocks are experiencing notable gaps. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
Preview: Protalix BioTherapeutics's Earnings ↗
 
Via Benzinga
News headline image
Earnings Outlook For Protalix BioTherapeutics ↗
 
Via Benzinga
News headline image
Protalix Revenue Jumps 16 Percent in Q2 ↗
Via The Motley Fool
News headline image
Top movers in Friday's session ↗
Curious about what's happening in today's session? Check out the latest stock movements and price changes. 
Via Chartmill
News headline image
Keep an eye on the top gainers and losers in Friday's session. ↗
Wondering how the US markets performed in the middle of the day on Friday? Discover the movers and shakers of today's session in our comprehensive analysis. 
Via Chartmill
News headline image
The market is filled with gapping stocks in Friday's session. ↗
The session on Friday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session. 
Via Chartmill
News headline image
Wondering what's happening in today's pre-market session? ↗
Let's have a look at what is happening on the US markets before the opening bell on Friday. Below you can find the top gainers and losers in today's pre-market session. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Earnings Scheduled For May 9, 2025 ↗
 
Via Benzinga
News headline image
Uncovering Potential: Protalix BioTherapeutics's Earnings Preview ↗
 
Via Benzinga
News headline image
Regulus Downgraded By Analysts After $1.7B Novartis Buyout Offer — Street Sees Limited Upside Ahead ↗
Regulus Therapeutics shares surged after Novartis announced a $1.7 billion acquisition, but analysts downgraded the stock citing limited upside. Retail sentiment remained bullish, with speculation of a... 
Via Stocktwits
Topics Stocks
News headline image
Evaluating PROTALIX BIOTHERAPEUTICS INC (NYSEARCA:PLX) using Mark Minervini’s winning stock formula ↗
A fundamental and technical analysis of (NYSEARCA:PLX): PROTALIX BIOTHERAPEUTICS INC (NYSEARCA:PLX) may be suited for high growth investing, we'll explore why in this article. 
Via Chartmill
News headline image
Does PROTALIX BIOTHERAPEUTICS INC (NYSEARCA:PLX) show the characteristics of a Minervini super stock? ↗
A fundamental and technical analysis of (NYSEARCA:PLX): Is PROTALIX BIOTHERAPEUTICS INC (NYSEARCA:PLX) suited for high growth investing? 
Via Chartmill
News headline image
Protalix BioTherapeutics Says With Debt Fully Repaid, It's Well-Positioned To Execute Strategy Through 2025 And Beyond ↗
Protalix saw record revenue growth in 2024, driven by increased sales to Chiesi, Pfizer, and Brazil. The company aims to start a Phase 2 trial for PRX-115 in 2025. 
Via Benzinga
News headline image
Earnings Scheduled For March 17, 2025 ↗
 
Via Benzinga
News headline image
PLX Stock Earnings: Protalix BioTherapeutics Misses EPS, Beats Revenue for Q2 2024 ↗
PLX stock results show that Protalix BioTherapeutics missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Earnings Scheduled For November 14, 2024 ↗
 
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.